Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Taysha Gene Therapies (TSHA) over the last 4 years, with Dec 2024 value amounting to -$0.36.

  • Taysha Gene Therapies' EPS (Weighted Average and Diluted) rose 10.00% to -$0.09 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.33, marking a year-over-year decrease of 152.38%. This contributed to the annual value of -$0.36 for FY2024, which is 62.50% up from last year.
  • Latest data reveals that Taysha Gene Therapies reported EPS (Weighted Average and Diluted) of -$0.36 as of FY2024, which was up 62.50% from -$0.96 recorded in FY2023.
  • In the past 5 years, Taysha Gene Therapies' EPS (Weighted Average and Diluted) registered a high of -$0.36 during FY2024, and its lowest value of -$4.64 during FY2021.
  • In the last 3 years, Taysha Gene Therapies' EPS (Weighted Average and Diluted) had a median value of -$0.96 in 2023 and averaged -$1.70.
  • Data for Taysha Gene Therapies' EPS (Weighted Average and Diluted) shows a peak YoY spiked of 74.60% (in 2023) over the last 5 years.
  • Taysha Gene Therapies' EPS (Weighted Average and Diluted) (Yearly) stood at -$4.64 in 2021, then rose by 18.53% to -$3.78 in 2022, then skyrocketed by 74.60% to -$0.96 in 2023, then skyrocketed by 62.50% to -$0.36 in 2024.